Cyclooxygenase-2 inhibition and cardiovascular events.
Pitt
Bertram
B
Pepine
Carl
C
Willerson
James T
JT
D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000188:drug therapy; D003327:Coronary Disease / Q000188:drug therapy; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D000077239:Meloxicam; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases; D013577:Syndrome; D013843:Thiazines / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D013843:Thiazines; D013844:Thiazoles; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D000077239:Meloxicam